All-in-One Rapid Fungal Testing

Point-of-care Diagnosis for Invasive Fungal infections with Lab-on-Chip

Fungal infections are often silent killers, causing immense suffering and claiming more lives each year than tuberculosis or malaria. Each year, over 1 billion people get a fungal infection globally, and approximately 6.55 million develop life-threatening infections, resulting in an estimated 3.75 million deaths. The population at risk for invasive fungal infection (IFI) continues to expand due to increasing numbers of hematopoietic stem cell and solid organ transplants, as well as the widespread use of immunosuppressive therapies. Notably, IFI—particularly invasive aspergillosis—are now also recognized in non-immunosuppressed individuals, including intensive care unit (ICU) patients and those with severe viral infections such as influenza and COVID-19.

Early and accurate diagnosis is essential for improving patient outcomes, but it remains a major challenge. Kelliop’s lab-on-chip technology enable clinical decisions at point-of-care. With RapidSeq126® device, F4Bio is developing a rapid and accurate all-in-one molecular diagnostics platform for invasive fungal infections detection. From collected sample to results — all within just 1 hour.